Search Results
Feb 25, 2026, 09:00 ET Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
The winning study, Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors, is led by research duo Laurence Zitvogel (Gustave Roussy and Paris-Saclay University) and
More news about: Bial Foundation
Feb 25, 2026, 09:00 ET El descubrimiento que vincula las bacterias intestinales con el tratamiento del cáncer gana el Premio Bial
El estudio ganador, Gut microbiome influences efficacy of PD 1–based immunotherapy against epithelial tumors, está dirigido por el dúo de investigación Laurence Zitvogel (Gustave Roussy y Universidad
More news about: Bial Foundation
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037's clinically meaningful activity across multiple
More news about: Antengene Corporation Limited
Feb 24, 2026, 17:04 ET National Event Series "Parkinson's IQ + You" Arrives in Southern Nevada to Educate and Empower Parkinson's Disease Patients and Care Partners
2019, Parkinson's IQ + You events have traveled to 23 cities across the United States to educate and empower people living with Parkinson's disease (PD) and their loved ones. Registration is free and open to everyone at
More news about: The Michael J. Fox Foundation for Parkinson's Research
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Phase 3 HERIZON-GEA-01 results support zanidatamab as the HER2-targeted agent of choice in HER2+ 1L gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.Multiple registrational trials of zanidatamab are underway, including in metastatic breast cancer (mBC), supporting a broad development
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Phase 3 HERIZON-GEA-01 results support zanidatamab as the HER2-targeted agent of choice in HER2+ 1L gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.Multiple registrational trials of zanidatamab are underway, including in metastatic breast cancer (mBC), supporting a broad development
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
FDA approval for KEYTRUDA and its subcutaneous formulation KEYTRUDA QLEX plus paclitaxel for adults with PD-L1-positive platinum-resistant ovarian cancer. KEYTRUDA is the first PD-1 inhibitor approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma."For
More news about: USA News Group
Feb 24, 2026, 09:30 ET K12 Coalition™ Launches Teaching Channel+, the First Unified Professional Learning Solution Built for Districts
accessible, district-wide access to high-quality professional learning. By bundling its extensive library of videos, self-paced professional development (PD) courses, and instructional coaching tools into a single, easy-to-use interface, Teaching Channel+ delivers a level of integration unmatched in the K-12
More news about: K12 Coalition
Feb 24, 2026, 08:55 ET New National Agenda Paves the Way for Improved Parkinson's Care
address the most pressing challenges in PD care. Their corresponding solutions are grounded in evidence-based best practices and the lived experience of people with PD and their care partners. Each solution includes short- and long-term actions to transform PD care:Build Community
More news about: Parkinson's Foundation
Feb 23, 2026, 13:11 ET New EduFable™ book from Dr. Brad Johnson highlights transformational leadership in schools
Global PD Teams and
More news about: Solution Tree
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex maintains an exclusive license to
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
Parkinson's disease – The world's first clinical-stage, allogeneic iPSC-derived, chemically induced dopaminergic progenitor cell therapy for PD; holds dual FDA FTD (August 2025) and RMAT (December 2025) designations; IND cleared in both China and the U.S.; now in Phase II trials in both China
More news about: iRegene Therapeutics Co., Ltd.
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
(ESCC)."About SugemalimabThe anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal
More news about: CStone Pharmaceuticals
Feb 20, 2026, 03:07 ET El modelo Toyota C-HR 2026 aporta un toque deportivo y elegante al SUV eléctrico compacto
sustituyen una conducción segura y atenta. El paquete de seguridad incluye:Sistema precolisión con detección de peatones (PCS c/PD, por sus siglas en inglés): Está diseñado para ayudar a detectar un vehículo, peatón, ciclista o motociclista y proporcionar una advertencia sonora/visual
More news about: Toyota Motor North America
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented
More news about: Johnson & Johnson
Feb 19, 2026, 07:00 ET Compugen to Participate in Upcoming Investor Conferences
TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The
More news about: Compugen Ltd.
Feb 18, 2026, 10:00 ET 2026 Toyota C-HR Puts Sporty, Stylish Spin on the Compact Electric SUV
substitute for safe and attentive driving. The safety suite includes:Pre-Collision System with Pedestrian Detection (PCS w/PD): Designed to help detect a vehicle, pedestrian, bicyclist, or motorcyclist and provide an audible/visual forward-collision warning under certain circumstances.
More news about: Toyota Motor North America
Feb 18, 2026, 09:18 ET Power Metallic Intercepts 20.40 Meters of 4.11% CuEqRec in Hole 25-046, and 8.60 Meters of 6.84% CuEqRec in Hole 25-045 at Lion
stringers, and disseminations). Subsequently the assay results indicated that the 20.4m of moderate copper mineralization (0.88% Cu) carried high values of Pd (5.01 g/t) as well as Pt and Au. Power Metallic is now developing logging procedures to help identify these higher-grade precious metal zones that form
More news about: Power Metallic Mines Inc.
Feb 18, 2026, 09:00 ET AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
HNSCC. Eligible participants must have failed prior therapy with chemotherapy and an anti-programmed cell death protein 1 inhibitor, also known as PD-1, or immune checkpoint inhibitor, administered in combination or sequentially. Failure of prior treatment may be due to disease progression or intolerance
More news about: AVEO, an LG Chem company
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
that is recurrent or metastatic and human papillomavirus (HPV)-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. RYBREVANT FASPRO™ is approved in multiple settings for the treatment of locally advanced or metastatic non-small cell lung cancer
More news about: Johnson & Johnson
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
in healthy adults, with pharmacokinetics (PK)/pharmacodynamics (PD) assessed in one study and safety and immunogenicity evaluated in both, compared with reference product NEUPOGEN. These studies demonstrated the biosimilarity in PD and PK parameters between FILKRI and NEUPOGEN and showed overall
More news about: Accord BioPharma
Feb 17, 2026, 07:42 ET Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Feb 17, 2026, 07:00 ET Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The
More news about: Compugen Ltd.
Feb 17, 2026, 01:39 ET Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness
animal models of cancer, the candidate drug has shown promising potentiation of immune-modulating treatments across several cancer types, including anti-PD-1 checkpoint inhibitors in colon cancer and standard of care treatment (temozolomide and radiation) in glioblastoma. Pharmacokinetic studies of BEA-17
More news about: Beactica Therapeutics AB
Feb 17, 2026, 01:35 ET Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness
animal models of cancer, the candidate drug has shown promising potentiation of immune-modulating treatments across several cancer types, including anti-PD-1 checkpoint inhibitors in colon cancer and standard of care treatment (temozolomide and radiation) in glioblastoma. Pharmacokinetic studies of BEA-17
More news about: Beactica Therapeutics AB